You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Alcon reported third-quarter sales of $2.7 billion, up 5%, and kept 2026 sales-growth guidance at approximately 6%. It narrowed core diluted EPS growth guidance to 12 to 14%; implantables sales fell 2% amid U.S. competitive pressure.
Alcon reported third-quarter 2026 sales of $2.7 billion, up 5%, and core diluted EPS of $0.91, up 15%. It tightened 2026 constant-currency sales growth guidance to +~6% and core diluted EPS growth guidance to +12% to +14%.
Useful current figures from the complete screener profile.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
ALC
this stock
Alcon Inc
|
$35.61B | -6.0% | +10.5% | — | 3.8% |
|
ISRG
Intuitive Surgical Inc
|
$153.77B | -21.7% | +20.5% | 53.8 | 2.0% |
|
BDX
Becton Dickinson & Co
|
$59.39B | — | +8.2% | 96.5 | 3.0% |
|
MDLN
Medline Inc.
|
$51.92B | -6.0% | +11.5% | — | 2.9% |
|
RMD
Resmed Inc
|
$33.69B | -0.6% | +13.4% | 21.8 | 7.4% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Alcon reported third-quarter 2026 sales of $2.7 billion, up 5%, and core diluted EPS of $0.91, up 15%. It tightened 2026 constant-currency sales growth guidance to +~6% and core diluted EPS growth guidance to +12% to +14%.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| ALC | -1.1% | +12.0% | +9.5% | +3.7% | -6.0% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -3.7% | +13.2% | +9.0% | +3.9% | -16.6% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
